Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05232838 · ClinicalTrials.gov registry record · NA
US Pilot Study of the CereVasc® eShunt® System in Normal Pressure Hydrocephalus
A NA study of Hydrocephalus and Hydrocephalus, Normal Pressure, sponsored by CereVasc.
- Active
- Registry status
- NA
- Development phase
- 50
- Enrollment target
- 11
- Study locations
NCT05232838: Active NA study of Hydrocephalus and Hydrocephalus, Normal Pressure, sponsored by CereVasc.
NCT05232838 is a NA study of Hydrocephalus and Hydrocephalus, Normal Pressure that is active but no longer recruiting, run by CereVasc. The registered enrollment target is 50 participants, below the 130-participant average among 17 other Hydrocephalus trials with a reported enrollment target (62% lower). The trial reports 11 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05232838, a NA study of Hydrocephalus and Hydrocephalus, Normal Pressure, is active but no longer recruiting, sponsored by CereVasc.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 50 participants
- Enrollment target
- 11
- Study locations
Study Summary
The eShunt® System is a minimally invasive method of treating communicating hydrocephalus. The eShunt System includes a proprietary eShunt Delivery System and the eShunt Implant, a permanent implant deployed in a minimally invasive, neuro-interventional procedure. The eShunt System is intended to shunt cerebrospinal fluid from the intracranial subarachnoid space to the venous system for the treatment of patients with normal pressure hydrocephalus, reducing disability due to symptoms including one or more of gait disturbance, cognitive dysfunction and urinary incontinence.
Primary Outcome
Rate of occurrence of device and/or procedure-related serious adverse events (SAEs)
Conditions Studied
Interventions
- DEVICE eShunt Implant
Study Locations (11)
New York
- University at Buffalo, - Buffalo
- NYU Langone Health - New York
- University of Rochester Medical Center - Rochester
- Montefiore Medical Center - The Bronx
Connecticut
- Yale University - New Haven
Florida
- Baptist Health - Jacksonville
Kansas
- University of Kansas Medical Center - Kansas City
Kentucky
- University of Kentucky Research Foundation - Lexington
Massachusetts
- Beth Israel Deaconess Medical Center - Boston
Rhode Island
- Rhode Island Hospital - Providence
Virginia
- Virginia Commonwealth University - Richmond
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2022-04-20 |
| Est. Completion | 2030-06-30 |
| Phase | NA |
What the registry record for NCT05232838 still lists
NCT05232838 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 50 participants, a relatively small participant target, below the 130-participant average among 17 other Hydrocephalus trials with a reported enrollment target (62% lower).
The record links to 2 conditions, with Hydrocephalus appearing as the primary indexed condition, and to 1 intervention - of which eShunt Implant is the first listed.
NCT05232838 lists 11 locations in 8 states (New York, Connecticut, Florida).
Frequently Asked Questions
What is clinical trial NCT05232838 about?
NCT05232838 is a clinical study titled "US Pilot Study of the CereVasc® eShunt® System in Normal Pressure Hydrocephalus". The eShunt® System is a minimally invasive method of treating communicating hydrocephalus. The eShunt System includes a proprietary eShunt Delivery System and the eShunt Implant, a permanent implant deployed in a minimally invasive, neuro-interventional procedure. The eShunt System is intended to sh...
What is the current status of trial NCT05232838?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 50 participants. The study started on 2022-04-20. Estimated completion is 2030-06-30.
What conditions does trial NCT05232838 study?
This clinical trial studies the following conditions: Hydrocephalus, Hydrocephalus, Normal Pressure.
What interventions are being tested in trial NCT05232838?
The interventions under investigation include: eShunt Implant (DEVICE).
Who is sponsoring clinical trial NCT05232838?
This trial is sponsored by CereVasc, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05232838 being conducted?
This trial has 11 study locations across Connecticut, Florida, Kansas, Kentucky, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hydrocephalus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05232838's enrollment target sits among peer trials
50 13th of 17 higher than 4 of 17 other Hydrocephalus trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hydrocephalus trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Assessment of CSF Shunt Flow and Headaches With a Thermal Measurement Device
RECRUITING · NA
-
EVD Drainage Data and Intracranial Pressure (ICP) Measurements
RECRUITING · NA
-
Light Therapy Device for Neonatal Intraventricular Hemorrhage Grade 3 and 4
RECRUITING · NA
-
Flow Detection in Open and Closed Shunt Valve Periods
RECRUITING · NA
-
Longitudinal Measurements of Flow in Cerebrospinal Fluid Shunts With a Wireless Thermal Anisotropy Measurement Device
RECRUITING · NA
-
MR Evaluation of Cerebrospinal Fluid (CSF) Dynamics
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00200889 · 50 participants · Early Phase 1
Mapping Auricular Vagus Nerve Circuitry
- NCT00409435 · 50 participants · Phase 2
A Study of Pyridostigmine in Postural Tachycardia Syndrome
- NCT01202305 · 50 participants
The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies
- NCT01225913 · 50 participants · Phase 4
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI